BriaCell Therapeutics Corp. (BCTX)

NASDAQ: BCTX · Real-Time Price · USD

0.8090

-0.0210 (-2.53%)

At close: Jul 24, 2025, 4:00 PM

0.8000

-0.0090 (-1.11%)

After-hours: Jul 24, 2025, 7:41 PM EDT

BriaCell Therapeutics Employees

BriaCell Therapeutics had 16 employees as of July 31, 2023. The number of employees increased by 10 or 166.67% compared to the previous year.

Employees

16

Change

10

Growth

166.67%

Revenue / Employee

n/a

Profits / Employee

-$1,214,666

Market Cap

5.47M

Employees Chart

Employees History

Date	Employees	Change	Growth
Jul 31, 2023	16	10	166.67%
Jul 31, 2021	6	0	-
Aug 1, 2019	6	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	94,300
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

BCTX News

8 days ago - BriaCell Therapeutics Announces Closing of $15 million Public Offering - GlobeNewsWire
9 days ago - BriaCell Therapeutics Announces Pricing of $15 million Public Offering - GlobeNewsWire
9 days ago - BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer - GlobeNewsWire
13 days ago - BriaCell's Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer - GlobeNewsWire
14 days ago - BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient - GlobeNewsWire
15 days ago - BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study - GlobeNewsWire
16 days ago - BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer - GlobeNewsWire
22 days ago - BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven - GlobeNewsWire